慢性阻塞性肺疾病是危害人类健康的常见病,反复发作的症状及进行性下降的肺功能大大降低了患者的生活质量。目前对COPD的治疗主要以缓解症状,减少急性发作为主,但难以延缓肺功能的减退,导致COPD的死亡率仍居高不下。近期研究发现肾素–...慢性阻塞性肺疾病是危害人类健康的常见病,反复发作的症状及进行性下降的肺功能大大降低了患者的生活质量。目前对COPD的治疗主要以缓解症状,减少急性发作为主,但难以延缓肺功能的减退,导致COPD的死亡率仍居高不下。近期研究发现肾素–血管紧张素系统(Ras)在肺组织局部高度表达,与多种肺疾病密切相关,血管紧张素转换酶抑制剂(ACEI)及血管紧张素-1型受体拮抗剂(ARB)的使用可减轻COPD的炎症反应,减少肺损伤,改善肺功能。因此,本文就RAS对COPD发展的影响做一综述。Chronic obstructive pulmonary disease (COPD) is a common disease that endangers human health. The recurrent symptoms and the progressively declining lung function have greatly reduced the quality of life of patients. At present, the treatment of COPD mainly focuses on relieving symptoms and reducing acute exacerbations, but it is difficult to delay the decline of lung function, resulting in the still high mortality rate of COPD. Recent studies have found that the renin-angiotensin system (RAS) is highly expressed in local lung tissues and is closely related to a variety of lung diseases. The use of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin type-1 receptor antagonists (ARB) can alleviate the inflammatory response of COPD, reduce lung injury and improve lung function. Therefore, this article reviews the impact of RAS on the development of COPD.展开更多
文摘慢性阻塞性肺疾病是危害人类健康的常见病,反复发作的症状及进行性下降的肺功能大大降低了患者的生活质量。目前对COPD的治疗主要以缓解症状,减少急性发作为主,但难以延缓肺功能的减退,导致COPD的死亡率仍居高不下。近期研究发现肾素–血管紧张素系统(Ras)在肺组织局部高度表达,与多种肺疾病密切相关,血管紧张素转换酶抑制剂(ACEI)及血管紧张素-1型受体拮抗剂(ARB)的使用可减轻COPD的炎症反应,减少肺损伤,改善肺功能。因此,本文就RAS对COPD发展的影响做一综述。Chronic obstructive pulmonary disease (COPD) is a common disease that endangers human health. The recurrent symptoms and the progressively declining lung function have greatly reduced the quality of life of patients. At present, the treatment of COPD mainly focuses on relieving symptoms and reducing acute exacerbations, but it is difficult to delay the decline of lung function, resulting in the still high mortality rate of COPD. Recent studies have found that the renin-angiotensin system (RAS) is highly expressed in local lung tissues and is closely related to a variety of lung diseases. The use of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin type-1 receptor antagonists (ARB) can alleviate the inflammatory response of COPD, reduce lung injury and improve lung function. Therefore, this article reviews the impact of RAS on the development of COPD.
